|
Name |
2-(Ethylthio)ethylamine
|
Molecular Formula | C4H11NS | |
IUPAC Name* |
2-ethylsulfanylethanamine
|
|
SMILES |
CCSCCN
|
|
InChI |
InChI=1S/C4H11NS/c1-2-6-4-3-5/h2-5H2,1H3
|
|
InChIKey |
HJCTVUWPHAZTLI-UHFFFAOYSA-N
|
|
Synonyms |
2-(Ethylthio)ethylamine; 36489-03-9; 2-(Ethylthio)ethanamine; 2-ethylsulfanylethanamine; 2-[Ethylthio]ethylamonium; 2-(ethylsulfanyl)ethanamine; Ethanamine, 2-(ethylthio)-; 2-(ethylsulfanyl)ethan-1-amine; 2-Aminoethylethyl sulfide; 2-ethylthioethylamine; 2-ethylthio-ethylamine; [2-(ethylthio)ethyl]amine; 2-(ethylsulfanyl)ethylamine; SCHEMBL152661; 2-(Ethylthio)ethylamine, 96%; DTXSID30189993; ALBB-011952; ZINC2146714; BBL104215; MFCD00014826; STL558079; AKOS000172300; MS-20057; DB-019507; FT-0611245; EN300-213208; F77934; F2147-1017
|
|
CAS | 36489-03-9 | |
PubChem CID | 148011 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 105.2 | ALogp: | 0.3 |
HBD: | 1 | HBA: | 2 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 51.3 | Aromatic Rings: | 0 |
Heavy Atoms: | 6 | QED Weighted: | 0.544 |
Caco-2 Permeability: | -5.424 | MDCK Permeability: | 0.00000578 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.016 |
Human Intestinal Absorption (HIA): | 0.011 | 20% Bioavailability (F20%): | 0.001 |
30% Bioavailability (F30%): | 0.001 |
Blood-Brain-Barrier Penetration (BBB): | 0.76 | Plasma Protein Binding (PPB): | 12.48% |
Volume Distribution (VD): | 1.158 | Fu: | 88.09% |
CYP1A2-inhibitor: | 0.322 | CYP1A2-substrate: | 0.475 |
CYP2C19-inhibitor: | 0.028 | CYP2C19-substrate: | 0.777 |
CYP2C9-inhibitor: | 0.004 | CYP2C9-substrate: | 0.675 |
CYP2D6-inhibitor: | 0.009 | CYP2D6-substrate: | 0.893 |
CYP3A4-inhibitor: | 0.009 | CYP3A4-substrate: | 0.303 |
Clearance (CL): | 8.084 | Half-life (T1/2): | 0.803 |
hERG Blockers: | 0.027 | Human Hepatotoxicity (H-HT): | 0.142 |
Drug-inuced Liver Injury (DILI): | 0.135 | AMES Toxicity: | 0.139 |
Rat Oral Acute Toxicity: | 0.82 | Maximum Recommended Daily Dose: | 0.04 |
Skin Sensitization: | 0.276 | Carcinogencity: | 0.577 |
Eye Corrosion: | 0.971 | Eye Irritation: | 0.534 |
Respiratory Toxicity: | 0.904 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000539 | 0.355 | D0V0LB | 0.250 | ||||
ENC000355 | 0.231 | D06CIE | 0.200 | ||||
ENC000017 | 0.208 | D03CHT | 0.184 | ||||
ENC000524 | 0.185 | D0FD0H | 0.176 | ||||
ENC000817 | 0.185 | D0OL6O | 0.167 | ||||
ENC000139 | 0.185 | D00WUF | 0.158 | ||||
ENC001178 | 0.184 | D09VAZ | 0.158 | ||||
ENC000760 | 0.182 | D05KEZ | 0.158 | ||||
ENC000137 | 0.182 | D00AMQ | 0.158 | ||||
ENC000550 | 0.182 | D01QLH | 0.152 |